Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.

Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, Diggelmann S, Limani F, Schlenker R, Hüsser T, Richter W, Bray-French K, Hinton H, Giusti AM, Freimoser-Grundschober A, Lariviere L, Neumann C, Klein C, Umaña P.

Clin Cancer Res. 2018 May 1. doi: 10.1158/1078-0432.CCR-18-0455. [Epub ahead of print]

PMID:
29716920
2.

A Syst-OMICS Approach to Ensuring Food Safety and Reducing the Economic Burden of Salmonellosis.

Emond-Rheault JG, Jeukens J, Freschi L, Kukavica-Ibrulj I, Boyle B, Dupont MJ, Colavecchio A, Barrere V, Cadieux B, Arya G, Bekal S, Berry C, Burnett E, Cavestri C, Chapin TK, Crouse A, Daigle F, Danyluk MD, Delaquis P, Dewar K, Doualla-Bell F, Fliss I, Fong K, Fournier E, Franz E, Garduno R, Gill A, Gruenheid S, Harris L, Huang CB, Huang H, Johnson R, Joly Y, Kerhoas M, Kong N, Lapointe G, Larivière L, Loignon S, Malo D, Moineau S, Mottawea W, Mukhopadhyay K, Nadon C, Nash J, Ngueng Feze I, Ogunremi D, Perets A, Pilar AV, Reimer AR, Robertson J, Rohde J, Sanderson KE, Song L, Stephan R, Tamber S, Thomassin P, Tremblay D, Usongo V, Vincent C, Wang S, Weadge JT, Wiedmann M, Wijnands L, Wilson ED, Wittum T, Yoshida C, Youfsi K, Zhu L, Weimer BC, Goodridge L, Levesque RC.

Front Microbiol. 2017 Jun 2;8:996. doi: 10.3389/fmicb.2017.00996. eCollection 2017.

3.

Survival analysis and microarray profiling identify Cd40 as a candidate for the Salmonella susceptibility locus, Ity5.

Beatty SC, Yuki KE, Eva MM, Dauphinee S, Larivière L, Vidal SM, Malo D.

Genes Immun. 2016 Jan-Feb;17(1):19-29. doi: 10.1038/gene.2015.41. Epub 2015 Nov 12.

PMID:
26562079
4.

Brain activation in response to overt and covert fear and happy faces in women with borderline personality disorder.

Cullen KR, LaRiviere LL, Vizueta N, Thomas KM, Hunt RH, Miller MJ, Lim KO, Schulz SC.

Brain Imaging Behav. 2016 Jun;10(2):319-31. doi: 10.1007/s11682-015-9406-4.

5.

Architecture of the RNA polymerase II-Mediator core initiation complex.

Plaschka C, Larivière L, Wenzeck L, Seizl M, Hemann M, Tegunov D, Petrotchenko EV, Borchers CH, Baumeister W, Herzog F, Villa E, Cramer P.

Nature. 2015 Feb 19;518(7539):376-80. doi: 10.1038/nature14229. Epub 2015 Feb 4.

PMID:
25652824
6.

Model of the Mediator middle module based on protein cross-linking.

Larivière L, Plaschka C, Seizl M, Petrotchenko EV, Wenzeck L, Borchers CH, Cramer P.

Nucleic Acids Res. 2013 Nov;41(20):9266-73. doi: 10.1093/nar/gkt704. Epub 2013 Aug 11.

7.

An adolescent with nonsuicidal self-injury: a case and discussion of neurobiological research on emotion regulation.

Cullen KR, Westlund MK, LaRiviere LL, Klimes-Dougan B.

Am J Psychiatry. 2013 Aug;170(8):828-31. doi: 10.1176/appi.ajp.2013.12121598.

8.

Structure of the Mediator head module.

Larivière L, Plaschka C, Seizl M, Wenzeck L, Kurth F, Cramer P.

Nature. 2012 Dec 20;492(7429):448-51. doi: 10.1038/nature11670. Epub 2012 Oct 31.

PMID:
23123849
9.

Comparative dynamic transcriptome analysis (cDTA) reveals mutual feedback between mRNA synthesis and degradation.

Sun M, Schwalb B, Schulz D, Pirkl N, Etzold S, Larivière L, Maier KC, Seizl M, Tresch A, Cramer P.

Genome Res. 2012 Jul;22(7):1350-9. doi: 10.1101/gr.130161.111. Epub 2012 Mar 30.

10.

A structural perspective on Mediator function.

Larivière L, Seizl M, Cramer P.

Curr Opin Cell Biol. 2012 Jun;24(3):305-13. doi: 10.1016/j.ceb.2012.01.007. Epub 2012 Feb 15. Review.

PMID:
22341791
11.

Impact of Usp18 and IFN signaling in Salmonella-induced typhlitis.

Richer E, Yuki KE, Dauphinee SM, Larivière L, Paquet M, Malo D.

Genes Immun. 2011 Oct;12(7):531-43. doi: 10.1038/gene.2011.38. Epub 2011 May 26.

PMID:
21614019
12.

Mediator head subcomplex Med11/22 contains a common helix bundle building block with a specific function in transcription initiation complex stabilization.

Seizl M, Larivière L, Pfaffeneder T, Wenzeck L, Cramer P.

Nucleic Acids Res. 2011 Aug;39(14):6291-304. doi: 10.1093/nar/gkr229. Epub 2011 Apr 15.

13.

Structure and VP16 binding of the Mediator Med25 activator interaction domain.

Vojnic E, Mourão A, Seizl M, Simon B, Wenzeck L, Larivière L, Baumli S, Baumgart K, Meisterernst M, Sattler M, Cramer P.

Nat Struct Mol Biol. 2011 Apr;18(4):404-9. doi: 10.1038/nsmb.1997. Epub 2011 Mar 6.

PMID:
21378965
14.

A tandem SH2 domain in transcription elongation factor Spt6 binds the phosphorylated RNA polymerase II C-terminal repeat domain (CTD).

Sun M, Larivière L, Dengl S, Mayer A, Cramer P.

J Biol Chem. 2010 Dec 31;285(53):41597-603. doi: 10.1074/jbc.M110.144568. Epub 2010 Oct 6.

15.

Architecture of the RNA polymerase II-TFIIF complex revealed by cross-linking and mass spectrometry.

Chen ZA, Jawhari A, Fischer L, Buchen C, Tahir S, Kamenski T, Rasmussen M, Lariviere L, Bukowski-Wills JC, Nilges M, Cramer P, Rappsilber J.

EMBO J. 2010 Feb 17;29(4):717-26. doi: 10.1038/emboj.2009.401. Epub 2010 Jan 21.

16.

Identification, structure, and functional requirement of the Mediator submodule Med7N/31.

Koschubs T, Seizl M, Larivière L, Kurth F, Baumli S, Martin DE, Cramer P.

EMBO J. 2009 Jan 7;28(1):69-80. doi: 10.1038/emboj.2008.254. Epub 2008 Dec 4.

17.

Structure-system correlation identifies a gene regulatory Mediator submodule.

Larivière L, Seizl M, van Wageningen S, Röther S, van de Pasch L, Feldmann H, Strässer K, Hahn S, Holstege FC, Cramer P.

Genes Dev. 2008 Apr 1;22(7):872-7. doi: 10.1101/gad.465108.

18.

Crystal structure and functional analysis identify the P-loop containing protein YFH7 of Saccharomyces cerevisiae as an ATP-dependent kinase.

Gueguen-Chaignon V, Chaptal V, Larivière L, Costa N, Lopes P, Morera S, Nessler S.

Proteins. 2008 May 1;71(2):804-12.

PMID:
18004758
19.

Molecular genetic analysis of two loci (Ity2 and Ity3) involved in the host response to infection with Salmonella typhimurium using congenic mice and expression profiling.

Sancho-Shimizu V, Khan R, Mostowy S, Larivière L, Wilkinson R, Riendeau N, Behr M, Malo D.

Genetics. 2007 Oct;177(2):1125-39. Epub 2007 Jul 29.

20.

Hepatic lipin 1beta expression is diminished in insulin-resistant obese subjects and is reactivated by marked weight loss.

Croce MA, Eagon JC, LaRiviere LL, Korenblat KM, Klein S, Finck BN.

Diabetes. 2007 Sep;56(9):2395-9. Epub 2007 Jun 11.

21.

Doing the right thing: infants' selection of actions to imitate from observed event sequences.

Brugger A, Lariviere LA, Mumme DL, Bushnell EW.

Child Dev. 2007 May-Jun;78(3):806-24.

PMID:
17517006
22.

Structure and TBP binding of the Mediator head subcomplex Med8-Med18-Med20.

Larivière L, Geiger S, Hoeppner S, Röther S, Strässer K, Cramer P.

Nat Struct Mol Biol. 2006 Oct;13(10):895-901. Epub 2006 Sep 10.

PMID:
16964259
23.

Incremental expression of Tlr4 correlates with mouse resistance to Salmonella infection and fine regulation of relevant immune genes.

Roy MF, Larivière L, Wilkinson R, Tam M, Stevenson MM, Malo D.

Genes Immun. 2006 Jul;7(5):372-83. Epub 2006 Jun 1. Erratum in: Genes Immun. 2006 Jul;7(5):437.

PMID:
16738669
24.

Influence of Slc11a1 on the outcome of Salmonella enterica serovar Enteritidis infection in mice is associated with Th polarization.

Caron J, Larivière L, Nacache M, Tam M, Stevenson MM, McKerly C, Gros P, Malo D.

Infect Immun. 2006 May;74(5):2787-802.

25.

X-ray structure of a domain-swapped dimer of Ser46-phosphorylated Crh from Bacillus subtilis.

Chaptal V, Larivière L, Gueguen-Chaignon V, Galinier A, Nessler S, Moréra S.

Proteins. 2006 Apr 1;63(1):249-51. No abstract available.

PMID:
16411239
26.

Structural evidence of a passive base-flipping mechanism for AGT, an unusual GT-B glycosyltransferase.

Larivière L, Sommer N, Moréra S.

J Mol Biol. 2005 Sep 9;352(1):139-50.

PMID:
16081100
27.

A potential link between muscle peroxisome proliferator- activated receptor-alpha signaling and obesity-related diabetes.

Finck BN, Bernal-Mizrachi C, Han DH, Coleman T, Sambandam N, LaRiviere LL, Holloszy JO, Semenkovich CF, Kelly DP.

Cell Metab. 2005 Feb;1(2):133-44.

28.

Structural evidence of a passive base-flipping mechanism for beta-glucosyltransferase.

Larivière L, Moréra S.

J Biol Chem. 2004 Aug 13;279(33):34715-20. Epub 2004 Jun 3.

30.

Overexpression of Toll-like receptor 4 amplifies the host response to lipopolysaccharide and provides a survival advantage in transgenic mice.

Bihl F, Salez L, Beaubier M, Torres D, Larivière L, Laroche L, Benedetto A, Martel D, Lapointe JM, Ryffel B, Malo D.

J Immunol. 2003 Jun 15;170(12):6141-50.

31.
32.

Crystallization and preliminary crystallographic study of a ternary complex between the T4 phage beta-glucosyltransferase, uridine diphosphoglucose and a DNA fragment containing an abasic site.

Larivière L, Kurzeck J, Aschke-Sonnenborn U, Rüger W, Moréra S.

Acta Crystallogr D Biol Crystallogr. 2002 Sep;58(Pt 9):1484-6. Epub 2002 Aug 23.

PMID:
12198310
33.

High resolution crystal structures of T4 phage beta-glucosyltransferase: induced fit and effect of substrate and metal binding.

Moréra S, Larivière L, Kurzeck J, Aschke-Sonnenborn U, Freemont PS, Janin J, Rüger W.

J Mol Biol. 2001 Aug 17;311(3):569-77.

PMID:
11493010
34.

LPS-hyporesponsiveness of mnd mice is associated with a mutation in Toll-like receptor 4.

Bihl F, Larivière L, Qureshi ST, Flaherty L, Malo D.

Genes Immun. 2001 Feb;2(1):56-9.

35.

Gleason grading of prostatic biopsies.

Milette F, Larivière L, Piché J.

Am J Surg Pathol. 2000 Oct;24(10):1443-4. No abstract available.

PMID:
11023113
36.

Cloning and characterization of the murine toll-like receptor 5 (Tlr5) gene: sequence and mRNA expression studies in Salmonella-susceptible MOLF/Ei mice.

Sebastiani G, Leveque G, Larivière L, Laroche L, Skamene E, Gros P, Malo D.

Genomics. 2000 Mar 15;64(3):230-40.

PMID:
10756091
37.

Cutting edge: functional characterization of the effect of the C3H/HeJ defect in mice that lack an Lpsn gene: in vivo evidence for a dominant negative mutation.

Vogel SN, Johnson D, Perera PY, Medvedev A, Larivière L, Qureshi ST, Malo D.

J Immunol. 1999 May 15;162(10):5666-70.

38.

Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4)

Qureshi ST, Larivière L, Leveque G, Clermont S, Moore KJ, Gros P, Malo D.

J Exp Med. 1999 Feb 15;189(4):615-25. Erratum in: J Exp Med 1999 May 3;189(9):following 1518.

39.

A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.

Sutherland LR, Martin F, Bailey RJ, Fedorak RN, Poleski M, Dallaire C, Rossman R, Saibil F, Lariviere L.

Gastroenterology. 1997 Apr;112(4):1069-77.

PMID:
9097988
40.

A high-resolution map in the chromosomal region surrounding the Lps locus.

Qureshi ST, Larivière L, Sebastiani G, Clermont S, Skamene E, Gros P, Malo D.

Genomics. 1996 Feb 1;31(3):283-94.

PMID:
8838309
41.

Antianginal efficacy and safety of controlled-delivery diltiazem QD versus an equivalent dose of immediate-release diltiazem TID.

Klinke WP, Baird M, Juneau M, Waters D, Warnica W, Lakhani Z, Annable L, Boulet AP, Larivière L.

Cardiovasc Drugs Ther. 1995 Apr;9(2):319-30.

PMID:
7662599
42.

Three-month efficacy and safety of once-daily diltiazem in chronic stable angina pectoris.

Nadeau C, Hilton D, Savard D, Morin Y, Baird M, Alexander M, Langer G, Roth D, Boulet AP, Larivière L.

Am J Cardiol. 1995 Mar 15;75(8):555-8.

PMID:
7710563
43.

Role of the beta-lactamase of Campylobacter jejuni in resistance to beta-lactam agents.

Lachance N, Gaudreau C, Lamothe F, Larivière LA.

Antimicrob Agents Chemother. 1991 May;35(5):813-8.

44.

Pharmacokinetics of oral diltiazem and five of its metabolites in patients with chronic renal failure.

Tawashi M, Marc-Aurèle J, Bichet D, Spénard J, Larivière L, Plante D, Caillé G.

Biopharm Drug Dispos. 1991 Mar;12(2):95-104.

PMID:
2031997
45.

Pharmacokinetics of intravenous diltiazem and five of its metabolites in patients with chronic renal failure and in healthy volunteers.

Tawashi M, Marc-Aurèle J, Bichet D, Spénard J, Larivière L, Plante D, Caillé G.

Biopharm Drug Dispos. 1991 Mar;12(2):105-12.

PMID:
2031991
46.

Placebo-controlled comparative study of the anxiolytic activity and of the pharmacokinetics of oral and sublingual lorazepam in generalized anxiety.

Spénard J, Caillé G, de Montigny C, Vézina M, Ouellette J, Larivière L, Trudel F.

Biopharm Drug Dispos. 1988 Sep-Oct;9(5):457-64.

PMID:
3066417
47.

Effect of clavulanic acid on susceptibility of Campylobacter jejuni and Campylobacter coli to eight beta-lactam antibiotics.

Gaudreau CL, Lariviere LA, Lauzer JC, Turgeon FF.

Antimicrob Agents Chemother. 1987 Jun;31(6):940-2.

48.

The effect of administration of phenytoin on the pharmacokinetics of isoxicam.

Caillé G, Du Souich P, Larivière L, Vézina M, Lacasse Y.

Biopharm Drug Dispos. 1987 Jan-Feb;8(1):57-61.

PMID:
3580513
49.

Susceptibility of clinical isolates of Campylobacter jejuni to twenty-five antimicrobial agents.

Lariviere LA, Gaudreau CL, Turgeon FF.

J Antimicrob Chemother. 1986 Dec;18(6):681-5.

PMID:
3493235
50.

The effects of low and moderate doses of alcohol on the pharmacokinetic parameters of zopiclone.

Larivière L, Caillé G, Elie R.

Biopharm Drug Dispos. 1986 Mar-Apr;7(2):207-10. No abstract available.

PMID:
3708125

Supplemental Content

Loading ...
Support Center